文献速递其他结缔组织病

利妥昔单抗治疗系统性硬化症的安全性与有效性(DESIRES研究)

Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial.
PubMed 文献 · Lancet Rheumatol · 2021-05-26

DESIRES 是一项在日本四家医院开展的双盲、研究者发起的随机安慰剂对照试验,纳入 56 例符合 2013 ACR/EULAR 分类标准且 mRSS≥10 的系统性硬化症患者,按 1:1 随机接受利妥昔单抗 375 mg/m2 每周一次共 4 周或安慰剂。不良事件两组相似,最常见为上呼吸道感染,随访期间无死亡。

要点

  • 不良事件发生率两组相似,利妥昔单抗组 28/28(100%),安慰剂组 23/26(88%)。
  • 最常见不良事件为上呼吸道感染,利妥昔单抗组 11 例(39%),安慰剂组 10 例(38%);随访期间无死亡。

核心结论

  • 利妥昔单抗似为系统性硬化症有效且安全的治疗,是首个以皮肤硬化为主要终点显示利妥昔单抗疗效的临床试验。

研究设计与样本

  • 在日本四家医院开展的双盲、研究者发起的随机安慰剂对照试验,2017 年 11 月 28 日至 2018 年 11 月 6 日筛查 80 例,纳入 56 例(70%)并随机分配。
  • 纳入 20–79 岁、符合 2013 ACR/EULAR 系统性硬化症分类标准、mRSS≥10 且预期生存至少 6 个月的患者,按 1:1 随机接受静脉利妥昔单抗 375 mg/m2 或安慰剂每周一次共 4 周。
  • 主要终点为治疗开始后 24 周 mRSS 绝对变化,在至少接受一剂研究治疗且有一次终点评估的患者中测量。

主要发现

  • 利妥昔单抗组 27/28(96%)和安慰剂组 22/28(79%)患者至少接受一剂分配治疗并完成 24 周随访。
  • 不良事件利妥昔单抗组 28/28(100%)、安慰剂组 23/26(88%);每组各 1 例严重不良事件导致治疗中断(利妥昔单抗组血清白蛋白降低,安慰剂组胆酶升高)。
  • 最常见不良事件为上呼吸道感染,利妥昔单抗组 11 例(39%),安慰剂组 10 例(38%);随访期间无死亡。

临床怎么用

  • 对于符合 2013 ACR/EULAR 分类标准且 mRSS≥10 的系统性硬化症患者,利妥昔单抗 375 mg/m2 每周一次共 4 周可考虑用于改善皮肤硬化。
  • 治疗期间应监测不良事件,尤其是上呼吸道感染,并注意严重不良事件导致治疗中断的可能。

局限性

  • 原文指出本研究存在一些局限性,但未具体说明。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Systemic sclerosis is a connective tissue disease characterised by multiorgan fibrosis with an autoimmune background and poor prognosis. Although a few drugs have shown some efficacy in treating the disease, there remains a great unmet medical need. We aimed to investigate the efficacy and safety of rituximab in patients with systemic sclerosis. METHODS: We did a double-blind, investigator-initiated, randomised, placebo-controlled trial at four hospitals in Japan. Patients aged 20-79 years, who fulfilled the 2013 American College of Rheumatology and European League Against Rheumatism classification criteria for systemic sclerosis, with a modified Rodnan Skin Score (mRSS) of 10 or greater, and an expected survival of at least 6 months were randomly assigned (1:1) to receive intravenous rituximab (375 mg/m2) or placebo once per week for 4 weeks. Patients and investigators were masked to treatment allocation. The primary endpoint was the absolute change in mRSS 24 weeks after initiation of study treatment, measured in all patients who received at least one dose of study treatment and had one endpoint assessment. This study is registered with ClinicalTrials.gov, NCT04274257, and UMIN-CTR, UMIN000030139. FINDINGS: Between Nov 28, 2017, and Nov 6, 2018, 80 individuals were screened and 56 (70%) were enrolled and randomly assigned; 51 (91%) were women and five (9%) were men. 27 (96%) of 28 patients in the rituximab group and 22 (79%) of 28 patients in the placebo group received at least one dose of their allocated treatment and completed 24 weeks of follow-up. The absolute change in mRSS 24 weeks after initiation of study treatment was lower in the rituximab group than in the placebo group (-6·30 in the rituximab group vs 2·14 in the placebo group; difference -8·44 [95% CI -11·00 to -5·88]; p<0·0001). Adverse events were similar in both groups and occurred in 28 (100%) of 28 patients in the rituximab group and 23 (88%) of 26 patients in the placebo group. One serious adverse event leading to treatment discontinuation occurred in one patient in each group (decreased serum albumin in the rituximab group and biliary enzyme increase in the placebo group). The most common adverse event was upper respiratory infection, which occurred in 11 patients (39%) in the rituximab group and ten patients (38%) in the placebo group. There were no deaths during follow-up. INTERPRETATION: Rituximab appears to be an effective and safe treatment for systemic sclerosis. Although this study has some limitations, this is the first clinical trial to show efficacy of rituximab with skin sclerosis as the primary endpoint. FUNDING: Japan Agency for Medical Research and Development (AMED), Zenyaku Kogyo. TRANSLATION: For the Japanese translation of the abstract see Supplementary Materials section.

来源:Lancet Rheumatol,查看原文。版权归原作者所有。

引用

  1. Ebata S, Yoshizaki A, Oba K, et al. Safety and efficacy of rituximab in systemic sclerosis (DESIRES): a double-blind, investigator-initiated, randomised, placebo-controlled trial. Lancet Rheumatol. 2021. PMID: 38279402. doi:10.1016/S2665-9913(21)00107-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。